Skip to main content

Canada Clears SQI’s Celiac Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics has received clearance from the Canadian government to market its biomarker-based microarray test for celiac disease, which runs on its multiplex testing kit, the Toronto-based company said today.

Health Canada has given a medical device license to SQI’s IgX Plex Celiac microarray test kit, which measures four biomarkers, for use on the SQiDworks platform.

Celiac disease is a digestive tract condition caused by the consumption of gluten that causes an immune reaction in the small intestine leading to damage to its surface and affecting its ability to absorb nutrients.

"As more assays become commercially available, the potential return on investment for labs that are considering purchasing the [SQI] technology increases, which may ultimately accelerate SQI's revenue ramp,” company President and CEO Claude Ricks said in a statement.

The company also said that it has submitted a 510(k) application with the US Food and Drug Administration for its Plex Celiac Assay and the SQiDworks diagnostics platform, and that the regulatory approval process is currently “on track.”

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.